Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

Can advanced-stage ovarian cancer be cured?

Abstract

Approximately 20% of women with advanced-stage ovarian cancer survive beyond 12 years after treatment and are effectively cured. Initial therapy for ovarian cancer comprises surgery and chemotherapy, and is given with the goal of eradicating as many cancer cells as possible. Indeed, the three phases of therapy are as follows: debulking surgery to remove as much of the cancer as possible, preferably to a state of no visible residual disease; chemotherapy to eradicate any microscopic disease that remains present after surgery; and second-line or maintenance therapy, which is given to delay disease progression among patients with tumour recurrence. If no cancer cells remain after initial therapy is completed, a cure is expected. By contrast, if residual cancer cells are present after initial treatment, then disease recurrence is likely. Thus, the probability of cure is contingent on the combination of surgery and chemotherapy effectively eliminating all cancer cells. In this Perspectives article, I present the case that the probability of achieving a cancer-free state is maximized through a combination of maximal debulking surgery and intraperitoneal chemotherapy. I discuss the evidence indicating that by taking this approach, cures could be achieved in up to 50% of women with advanced-stage ovarian cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: A model of ovarian cancer treatment outcome.

Similar content being viewed by others

References

  1. Ferlay, J. et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [online], (2013).

    Google Scholar 

  2. Cress, R. D., Chen, Y. S., Morris, C. R., Petersen, M. & Leiserowitz, G. S. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet. Gynecol. 126, 491–497 (2015).

    Article  Google Scholar 

  3. Sopik, V., Iqbal, J., Rosen, B. & Narod, S. A. Why have ovarian cancer mortality rates declined? Part I: incidence. Gynecol. Oncol. http://dx.doi.org/10.1016/j.ygyno.2015.06.017 (2015).

  4. National Cancer Institute. SEER stat fact sheets: ovary cancer [online], (2015).

  5. Sopik, V., Iqbal, J., Rosen, B. & Narod, S. A. Why have ovarian cancer mortality rates declined? Part II: case-fatality. Gynecol. Oncol. 138, 741–749 (2015).

    Article  Google Scholar 

  6. McLaughlin, J. R. et al. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J. Natl Cancer Inst. 105, 141–148 (2013).

    Article  CAS  Google Scholar 

  7. Bowtell, B. et al. Rethinking ovarian cancer II: a roadmap for reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668–679 (2015).

    Article  CAS  Google Scholar 

  8. Morgan, R. J. et al. Ovarian cancer, version 3.2014. J. Natl Compr. Canc. Netw. 11, 1199–1209 (2014).

    Article  Google Scholar 

  9. Nick, A. M., Coleman, R. L., Ramirez, P. T. & Sood, A. K. A framework for a personalized surgical approach to ovarian cancer. Nat. Rev. Clin. Oncol. 12, 239–245 (2015).

    Article  CAS  Google Scholar 

  10. Fagotti, A. et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. Gynecol. Oncol. 131, 341–346 (2013).

    Article  CAS  Google Scholar 

  11. Burger, R. A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473–2483 (2011).

    Article  CAS  Google Scholar 

  12. Oza, A. M. et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 16, 87–97 (2015).

    Article  CAS  Google Scholar 

  13. Pujade-Lauraine, E. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 32, 1302–1308 (2014).

    Article  CAS  Google Scholar 

  14. Perren, T. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484–2496 (2011).

    Article  CAS  Google Scholar 

  15. Vergote, I. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363, 943–953 (2010).

    Article  CAS  Google Scholar 

  16. Kehoe, S. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386, 249–257 (2015).

    Article  Google Scholar 

  17. Goodman, B. Lifesaving chemo for ovarian cancer is underused. WebMD [online], (2015).

    Google Scholar 

  18. Rosen, B. et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol. Oncol. 134, 462–467 (2014).

    Article  CAS  Google Scholar 

  19. Colombo, P. E. et al. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer. Gynecol. Oncol. 135, 223–230 (2014).

    Article  CAS  Google Scholar 

  20. Rauh-Hain, J. A. et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol. Oncol. 129, 63–68 (2013).

    Article  CAS  Google Scholar 

  21. du Bois, A. et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115, 1234–1244 (2009).

    Article  CAS  Google Scholar 

  22. Horowitz, N. et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J. Clin. Oncol. 33, 937–943 (2015).

    Article  Google Scholar 

  23. Chang, S. J., Hodeib, M, Chang, J & Bristow, R. E. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol. Oncol. 130, 493–498 (2013).

    Article  Google Scholar 

  24. McGuire, W. P. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1–6 (1996).

    Article  CAS  Google Scholar 

  25. Ozols, R. F. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21, 3194–3200 (2003).

    Article  CAS  Google Scholar 

  26. Tewari, D. et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 33, 1460–1466 (2015).

    Article  CAS  Google Scholar 

  27. Barlin, J. N. et al. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecol. Oncol. 125, 621–624 (2012).

    Article  CAS  Google Scholar 

  28. Gray, H. J., Shah, C. A., Swensen, R. E., Tamimi, H. K. & Goff, B. A. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. Gynecol. Oncol. 115, 340–344 (2010).

    Article  Google Scholar 

  29. Chin, S. N. et al. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma. Gynecol. Oncol. 112, 450–454 (2009).

    Article  CAS  Google Scholar 

  30. Alberts, D. S. et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335, 1950–1955 (1996).

    Article  CAS  Google Scholar 

  31. Katsumata, N. et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 14, 1020–1026 (2013).

    Article  CAS  Google Scholar 

  32. Wright, A. et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J. Clin. Oncol. 33, 2841–2847 (2015).

    Article  CAS  Google Scholar 

  33. Engel, J. et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur. J. Cancer. 38, 2435–2445 (2002).

    Article  CAS  Google Scholar 

  34. Candido-dos-Reis, F. J. et al. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clin. Cancer Res. 21, 652–657 (2015).

    Article  CAS  Google Scholar 

  35. Kotsopoulos, J. et al. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. Gynecol. Oncol. http://dx.doi.org/10.1016/j.ygyno.2015.11.009 (2015).

  36. Tutt, A. et al. Abstract S3-01: the TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Res. 75, S3-01 (2012).

    Google Scholar 

  37. Bolton, K. L. et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307, 382–390 (2012).

    Article  CAS  Google Scholar 

  38. Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489–494 (2015).

    Article  CAS  Google Scholar 

  39. Halsted, W. S. The results of operations for the cure of cancer of the breast performed at Johns Hopkins Hospital from June 1889 to January 1894. Ann. Surg. 20, 497–555 (1894).

    Article  CAS  Google Scholar 

  40. Amate, P. et al. Ovarian cancer: sites of recurrence. Int. J. Gynecol. Cancer. 23, 1590–1596 (2013).

    Article  Google Scholar 

  41. Esselen, K. M. et al. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intaperitoneal chemotherapy. Gynecol. Oncol. 127, 51–54 (2012).

    Article  CAS  Google Scholar 

  42. Landrum, L. M. et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol. Oncol. 130, 12–18 (2013).

    Article  Google Scholar 

  43. Hess, K. et al. Metastatic patterns in adenocarcinoma. Cancer 106, 1624–1633 (2006).

    Article  Google Scholar 

  44. Lesnock, J. L. et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group study. Br. J. Cancer 108, 1231–1237 (2013).

    Article  CAS  Google Scholar 

  45. Fagotti, A. et al. Phase III SCORPION trial in epithelial ovarian cancer patients with high tumor load receiving PDS versus NACT: an interim analysis on peri-operative outcome. Gynecol. Oncol. 138 (Suppl. 1), 1–4 (2015).

    Article  Google Scholar 

  46. Suidan, R. et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol. Oncol. 134, 455–461 (2014).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

I thank Victoria Sopik, MSc, of the Women's College Research Institute, for reviewing the manuscript before submission.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Steven Narod.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Narod, S. Can advanced-stage ovarian cancer be cured?. Nat Rev Clin Oncol 13, 255–261 (2016). https://doi.org/10.1038/nrclinonc.2015.224

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2015.224

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer